Lysosomal Disease Treatment Market Expected to Reach $14.1 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Lysosomal Disease Treatment Market," The lysosomal disease treatment market was valued at $7.6 billion in 2021, and is estimated to reach $14.1 billion by 2031, growing at a CAGR of 6.4% from 2022 to 2031.

Lysosomal disease (LD) is a hereditary metabolic disorder brought on by inadequate lysosomal enzyme synthesis. Human body contains over 50 different forms of lysosomal storage disorders. In addition, there are few choices for treating the illness. The lysosomal disease treatment market share is expected to expand as more research and development (R&D) activities are conducted in an effort to create an effective treatment. Expanding government programs and investments for development of innovative medications is expected to boost the market growth during the forecast period. Moreover, rise in prevalence of lysosomal disease treatment is expected to boost the lysosomal disease treatment market growth. Introduction of orphan medicines is also anticipated to fuel the market expansion.

Growth in awareness regarding preventative measures for lysosomal diseases and lysosomal disease treatment market trends are anticipated to propel the growth of lysosomal disease treatment market size. The lysosomal disease treatment market is also expected to grow, owing to expansion of pharmaceutical and healthcare industries. However, lack of effective treatments and their high-cost are the factors restrain the market growth. The demand for lysosomal disease treatment significantly decreased after the COVID-19 pandemic. The focus of medical professionals, governments, and general public has moved to containing spread of the virus as a result of quick expansion of the virus. It consequently decreased the need for lysosomal disease treatment. People also stopped going to clinics and hospitals unless they had an emergency. As a result, the COVID-19 pandemic caused severe disruptions in the market for treating lysosomal diseases. Lysosomal disease is group of inherent diseases affects the normal body fuctions of brain, skeletal and central nervous system. During the covid-19 period the need for lysosomal disease treatment decreased significantly. However, the diagnostic methods used for the lysosomal diseases are enzyme assay activity, optical fluorometry, mutation scanning, mass spectroscopy and DNA sequencing. In various hospitals screening of newborn for various test including lysosomal disease test is mandatory. According to the U.S. National Library of Medicine 1 in 40,000 to 60,000 males have Fabry's disease. Pompe’s syndrome is affecting about 1 in 40,000 people in the U.S. according to the National Organization for Rare Disorders. Moreover, Pompe’ syndrome affects about 1 in 40,000 people in the U.S., according to the National Organization for Rare Disorders

Coronavirus Severe acute respiration syndrome (SARS-CoV-2) is an infectious disease caused by the novel coronavirus (COVID-19), which originated in the Wuhan district in China in the late 2019, and since has spread to 212 countries. The virus was initially referred to as “novel coronavirus 2019” (2019-nCoV) by the WHO, However, on February 11, 2020, it was given the official name of SARS-CoV-2 by the International Committee on Taxonomy of Viruses. WHO declared COVID-19 as pandemic on March 11, 2020, and by September 1, 2020, over 28.1 million people have been infected globally with over 909,000 deaths. COVID-19 symptoms include fever, cough, and shortness of breath.

Nearly all industries have been impacted by the COVID-19. As coronavirus crises sweep the globe and force healthcare organizations to devote majority of their funds to fighting COVID-19, the outbreak of COVID-19 has resulted in a significant decline in demand for the lysosomal disease treatment across several sectors, particularly the health and pharmaceutical sector. The main cause of the interruptions experienced by patients getting treatment for lysosomal storage disorder in hospitals was the risk of infection. As a result, the COVID-19 outbreak is expected to slow the global market growth for treatments for lysosomal diseases, which will have a negative effect on the market's value in 2022 and beyond

By disease type, the Gaucher's disease segment dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to increase in incidences of lysosomal diseases and rise in awareness related to early diagnosis of lysosomal diseases.  

Depending on type of therapy, the enzyme replacement therapy segment dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to increasing research and development (R&D) activities to develop an efficient treatment.

On the basis of end user, the hospitals segment dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to rise in rare diseases and increase in success rate of treatment of lysosomal diseases.

Region wise, North America has the highest lysosomal disease treatment industry share in 2021. Furthermore, availability of products for treatment of lysosomal diseases and high disease prevalence are the major factors responsible for the market growth of this region.

Key findings of the study

• By disease type, the Gaucher's diseases segment dominated the market in 2021, and it is expected to remain dominant throughout the forecast period.
• On the basis of type of therapy, the enzyme replacement therapy segment dominated the market in 2021.
• By end user, the hospitals segment dominated the market in 2021.
• Region wise, North America dominated the market in 2021.